U.S. Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mehmet Oz announced on Monday that 600,000 seniors have enrolled in a new federal program to obtain GLP-1 weight-loss medications. The enrollment figure represents the first two months of the initiative's operation.
The federal program, known as the Medicare Bridge program, was established to increase availability for weight-loss treatments. The announcement follows the program's official launch in July 2026.
The Medicare Bridge program allows qualifying older Americans to access these medications for a monthly cost of $50. The medications include GLP-1 drugs, a class of treatments that have seen high levels of demand in the United States.
For individual participants, the program standardizes the cost of these treatments at $50 per month. This provides a specific price point for medications that the source describes as "highly sought-after." A person enrolled in the program would notice this fixed cost when filling their prescriptions for GLP-1 medications, which include products like Zepbound from Eli Lilly and Company.
The enrollment rate suggests a high level of demand for weight-loss treatments within the Medicare population. As the program continues, it will involve large-scale coordination between the federal government and pharmaceutical companies such as Eli Lilly and Novo Nordisk. What happens next involves the continued rollout of the program to the millions of eligible seniors mentioned by the administrator, though specific future deadlines or enrollment caps were not reported.